Evidence map›Paper›PMID 37355730›Full record

ArticleScientific reports2023

Automatic speaker diarization for natural conversation analysis in autism clinical trials.

James O'Sullivan, Guy Bogaarts, Philipp Schoenenberger, Julian Tillmann, David Slater, Nima Mesgarani, Eckhart Eule, Timothy Kilchenmann, Lorraine Murtagh, Joerg Hipp and 5 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Speaker Role Identification in Clinical Conversations.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · 2026
    Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

James O'SullivanRoche Innovation Center BaselF. Hoffmann-La Roche Ltd., Basel, Switzerland.
Guy BogaartsRoche Innovation Center BaselF. Hoffmann-La Roche Ltd., Basel, Switzerland.
Philipp SchoenenbergerNeuroscience Early Development, Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Julian TillmannNeuroscience Early Development, Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.
David SlaterRoche Innovation Center BaselF. Hoffmann-La Roche Ltd., Basel, Switzerland.
Nima MesgaraniMortimer B. Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY, 10027, USA.
Eckhart EuleNeuroscience Early Development, Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Timothy KilchenmannRoche Innovation Center BaselF. Hoffmann-La Roche Ltd., Basel, Switzerland.
Lorraine MurtaghNeuroscience & Rare Diseases, Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Joerg HippNeuroscience & Rare Diseases, Pharma Research & Early Development, Roche Innovation Center Basel, Basel, Switzerland.
Michael LindemannRoche Innovation Center BaselF. Hoffmann-La Roche Ltd., Basel, Switzerland.
Florian LipsmeierRoche Innovation Center BaselF. Hoffmann-La Roche Ltd., Basel, Switzerland. florian.lipsmeier@roche.com.
Wei-Yi ChengRoche Innovation Center New York, Roche TCRC Inc., New York, USA.
David NobbsRoche Innovation Center BaselF. Hoffmann-La Roche Ltd., Basel, Switzerland.
Christopher ChathamBiomarkers & Translational Technology, Neuroscience & Rare Diseases, Pharma Research & Early Development, Roche Innovation Center New York, New York, USA.
Roche (Switzerland) · CHColumbia University · USLa Roche College · US

Funding

Neurophysiology of robust speech perception in human superior temporal gyrusR01DC014279 · NIDCD · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Nima MESGARANI · 2015 to 2026
$5.3M
NIDCD NIH HHS R01 DC014279
6 · The paper itself

Abstract

Challenges in social communication is one of the core symptom domains in autism spectrum disorder (ASD). Novel therapies are under development to help individuals with these challenges, however the ability to show a benefit is dependent on a sensitive and reliable measure of treatment effect. Currently, measuring these deficits requires the use of time-consuming and subjective techniques. Objective measures extracted from natural conversations could be more ecologically relevant, and administered more frequently-perhaps giving them added sensitivity to change. While several studies have used automated analysis methods to study autistic speech, they require manual transcriptions. In order to bypass this time-consuming process, an automated speaker diarization algorithm must first be applied. In this paper, we are testing whether a speaker diarization algorithm can be applied to natural conversations between autistic individuals and their conversational partner in a natural setting at home over the course of a clinical trial. We calculated the average duration that a participant would speak for within their turn. We found a significant correlation between this feature and the Vineland Adaptive Behaviour Scales (VABS) expressive communication score (r = 0.51, p = 7 × 10

Indexed as

Autism Spectrum DisorderAutistic DisorderCommunicationHumansSpeech

Identifiers

PMID37355730
PMCPMC10290724
OpenAlexW4381890216

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.